The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension

Xiang Yang Zhu, Alejandro R. Chade, James D. Krier, Elena Daghini, Ronit Lavi, Angelo Guglielmotti, Amir Lerman, Lilach O Lerman

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Renal artery stenosis (RAS) causes renovascular hypertension and renal damage, which may result from tissue inflammation. We have previously shown that the kidney in RAS exhibits increased expression of monocyte chemoattractant protein (MCP)-1, but its contribution to renal injury remained unknown. This study tested the hypothesis that MCP-1 contributes to renal injury and dysfunction in the stenotic kidney. METHODS: Kidney hemodynamics, function, and endothelial function were quantified in pigs after 10 weeks of experimental RAS (n = 7), RAS supplemented with the MCP-1 inhibitor bindarit (RAS + bindarit, 50 mg/kg/day orally, n = 6), and normal controls (n = 8). Renal inflammation was assessed by the immunoreactivity of MCP-1, its receptor chemotactic cytokine receptor 2, and NFκB, and oxidative stress by nicotinamide adenine dinucleotide phosphate-oxidase expression and in-situ superoxide production. Renal microvascular density was evaluated by micro-CT and fibrosis by trichrome staining, collagen-I immunostaining, and hydroxyproline content. RESULTS: After 10 weeks of RAS, blood pressure was similarly elevated in RAS and RAS + bindarit. Compared with normal controls, stenotic RAS kidneys had decreased renal blood flow (5.4 ± 1.6 vs. 11.4 ± 1.0 ml/min/kg, P < 0.05) and glomerular filtration rate and impaired endothelial function, which were significantly improved in bindarit-treated RAS pigs (to 8.4 ± 0.8 ml/min/kg, P < 0.05 vs. RAS). Furthermore, bindarit markedly decreased tubulointerstitial (but not vascular) oxidative stress, inflammation, and fibrosis, and slightly increased renal microvascular density. The impaired renovascular endothelial function, increased oxidative-stress, and fibrosis in the contralateral kidney were also improved by bindarit. CONCLUSION: MCP-1 contributes to functional and structural impairment in the kidney in RAS, mainly in the tubulointerstitial compartment. Its inhibition confers renoprotective effects by blunting renal inflammation and thereby preserving the kidney in chronic RAS.

Original languageEnglish (US)
Pages (from-to)2063-2073
Number of pages11
JournalJournal of Hypertension
Volume27
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Renovascular Hypertension
Chemokine CCL2
Renal Artery Obstruction
Chemokines
Swine
Kidney
Inflammation
Oxidative Stress
Fibrosis
CCR2 Receptors
Cytokine Receptors
Renal Circulation
Hydroxyproline
Wounds and Injuries
Glomerular Filtration Rate
NADP
Superoxides
Blood Vessels
bindarit

Keywords

  • Bindarit
  • Monocyte chemoattractant protein-1
  • Renal artery stenosis
  • Renovascular hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. / Zhu, Xiang Yang; Chade, Alejandro R.; Krier, James D.; Daghini, Elena; Lavi, Ronit; Guglielmotti, Angelo; Lerman, Amir; Lerman, Lilach O.

In: Journal of Hypertension, Vol. 27, No. 10, 2009, p. 2063-2073.

Research output: Contribution to journalArticle

Zhu, Xiang Yang ; Chade, Alejandro R. ; Krier, James D. ; Daghini, Elena ; Lavi, Ronit ; Guglielmotti, Angelo ; Lerman, Amir ; Lerman, Lilach O. / The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. In: Journal of Hypertension. 2009 ; Vol. 27, No. 10. pp. 2063-2073.
@article{0686a1cf10034ba68d64e224c964c81d,
title = "The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension",
abstract = "Renal artery stenosis (RAS) causes renovascular hypertension and renal damage, which may result from tissue inflammation. We have previously shown that the kidney in RAS exhibits increased expression of monocyte chemoattractant protein (MCP)-1, but its contribution to renal injury remained unknown. This study tested the hypothesis that MCP-1 contributes to renal injury and dysfunction in the stenotic kidney. METHODS: Kidney hemodynamics, function, and endothelial function were quantified in pigs after 10 weeks of experimental RAS (n = 7), RAS supplemented with the MCP-1 inhibitor bindarit (RAS + bindarit, 50 mg/kg/day orally, n = 6), and normal controls (n = 8). Renal inflammation was assessed by the immunoreactivity of MCP-1, its receptor chemotactic cytokine receptor 2, and NFκB, and oxidative stress by nicotinamide adenine dinucleotide phosphate-oxidase expression and in-situ superoxide production. Renal microvascular density was evaluated by micro-CT and fibrosis by trichrome staining, collagen-I immunostaining, and hydroxyproline content. RESULTS: After 10 weeks of RAS, blood pressure was similarly elevated in RAS and RAS + bindarit. Compared with normal controls, stenotic RAS kidneys had decreased renal blood flow (5.4 ± 1.6 vs. 11.4 ± 1.0 ml/min/kg, P < 0.05) and glomerular filtration rate and impaired endothelial function, which were significantly improved in bindarit-treated RAS pigs (to 8.4 ± 0.8 ml/min/kg, P < 0.05 vs. RAS). Furthermore, bindarit markedly decreased tubulointerstitial (but not vascular) oxidative stress, inflammation, and fibrosis, and slightly increased renal microvascular density. The impaired renovascular endothelial function, increased oxidative-stress, and fibrosis in the contralateral kidney were also improved by bindarit. CONCLUSION: MCP-1 contributes to functional and structural impairment in the kidney in RAS, mainly in the tubulointerstitial compartment. Its inhibition confers renoprotective effects by blunting renal inflammation and thereby preserving the kidney in chronic RAS.",
keywords = "Bindarit, Monocyte chemoattractant protein-1, Renal artery stenosis, Renovascular hypertension",
author = "Zhu, {Xiang Yang} and Chade, {Alejandro R.} and Krier, {James D.} and Elena Daghini and Ronit Lavi and Angelo Guglielmotti and Amir Lerman and Lerman, {Lilach O}",
year = "2009",
doi = "10.1097/HJH.0b013e3283300192",
language = "English (US)",
volume = "27",
pages = "2063--2073",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension

AU - Zhu, Xiang Yang

AU - Chade, Alejandro R.

AU - Krier, James D.

AU - Daghini, Elena

AU - Lavi, Ronit

AU - Guglielmotti, Angelo

AU - Lerman, Amir

AU - Lerman, Lilach O

PY - 2009

Y1 - 2009

N2 - Renal artery stenosis (RAS) causes renovascular hypertension and renal damage, which may result from tissue inflammation. We have previously shown that the kidney in RAS exhibits increased expression of monocyte chemoattractant protein (MCP)-1, but its contribution to renal injury remained unknown. This study tested the hypothesis that MCP-1 contributes to renal injury and dysfunction in the stenotic kidney. METHODS: Kidney hemodynamics, function, and endothelial function were quantified in pigs after 10 weeks of experimental RAS (n = 7), RAS supplemented with the MCP-1 inhibitor bindarit (RAS + bindarit, 50 mg/kg/day orally, n = 6), and normal controls (n = 8). Renal inflammation was assessed by the immunoreactivity of MCP-1, its receptor chemotactic cytokine receptor 2, and NFκB, and oxidative stress by nicotinamide adenine dinucleotide phosphate-oxidase expression and in-situ superoxide production. Renal microvascular density was evaluated by micro-CT and fibrosis by trichrome staining, collagen-I immunostaining, and hydroxyproline content. RESULTS: After 10 weeks of RAS, blood pressure was similarly elevated in RAS and RAS + bindarit. Compared with normal controls, stenotic RAS kidneys had decreased renal blood flow (5.4 ± 1.6 vs. 11.4 ± 1.0 ml/min/kg, P < 0.05) and glomerular filtration rate and impaired endothelial function, which were significantly improved in bindarit-treated RAS pigs (to 8.4 ± 0.8 ml/min/kg, P < 0.05 vs. RAS). Furthermore, bindarit markedly decreased tubulointerstitial (but not vascular) oxidative stress, inflammation, and fibrosis, and slightly increased renal microvascular density. The impaired renovascular endothelial function, increased oxidative-stress, and fibrosis in the contralateral kidney were also improved by bindarit. CONCLUSION: MCP-1 contributes to functional and structural impairment in the kidney in RAS, mainly in the tubulointerstitial compartment. Its inhibition confers renoprotective effects by blunting renal inflammation and thereby preserving the kidney in chronic RAS.

AB - Renal artery stenosis (RAS) causes renovascular hypertension and renal damage, which may result from tissue inflammation. We have previously shown that the kidney in RAS exhibits increased expression of monocyte chemoattractant protein (MCP)-1, but its contribution to renal injury remained unknown. This study tested the hypothesis that MCP-1 contributes to renal injury and dysfunction in the stenotic kidney. METHODS: Kidney hemodynamics, function, and endothelial function were quantified in pigs after 10 weeks of experimental RAS (n = 7), RAS supplemented with the MCP-1 inhibitor bindarit (RAS + bindarit, 50 mg/kg/day orally, n = 6), and normal controls (n = 8). Renal inflammation was assessed by the immunoreactivity of MCP-1, its receptor chemotactic cytokine receptor 2, and NFκB, and oxidative stress by nicotinamide adenine dinucleotide phosphate-oxidase expression and in-situ superoxide production. Renal microvascular density was evaluated by micro-CT and fibrosis by trichrome staining, collagen-I immunostaining, and hydroxyproline content. RESULTS: After 10 weeks of RAS, blood pressure was similarly elevated in RAS and RAS + bindarit. Compared with normal controls, stenotic RAS kidneys had decreased renal blood flow (5.4 ± 1.6 vs. 11.4 ± 1.0 ml/min/kg, P < 0.05) and glomerular filtration rate and impaired endothelial function, which were significantly improved in bindarit-treated RAS pigs (to 8.4 ± 0.8 ml/min/kg, P < 0.05 vs. RAS). Furthermore, bindarit markedly decreased tubulointerstitial (but not vascular) oxidative stress, inflammation, and fibrosis, and slightly increased renal microvascular density. The impaired renovascular endothelial function, increased oxidative-stress, and fibrosis in the contralateral kidney were also improved by bindarit. CONCLUSION: MCP-1 contributes to functional and structural impairment in the kidney in RAS, mainly in the tubulointerstitial compartment. Its inhibition confers renoprotective effects by blunting renal inflammation and thereby preserving the kidney in chronic RAS.

KW - Bindarit

KW - Monocyte chemoattractant protein-1

KW - Renal artery stenosis

KW - Renovascular hypertension

UR - http://www.scopus.com/inward/record.url?scp=70350448297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350448297&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e3283300192

DO - 10.1097/HJH.0b013e3283300192

M3 - Article

C2 - 19730125

AN - SCOPUS:70350448297

VL - 27

SP - 2063

EP - 2073

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 10

ER -